Diagnósticos da América S.A (DASA3) fair value: what the stock is really worth
We calculate from audited financials what Diagnósticos da América S.A is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Diagnósticos da América S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range R$1.20 – R$63.42 · fair‑value band R$0.7200 – R$1.50 · the R$2.65 price screens above the R$1.15 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments.
Show more
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments. It also offers medical, property and vehicle rental, consultancy, and franchise contracting services. The company was formerly known as Laboratório Clínico Delboni Auriemo S.A. and changed its name to Diagnósticos da América S.A. in August 2000. Diagnósticos da América S.A. was founded in 1961 and is headquartered in São Paulo, Brazil.
Stock analysis
Diagnósticos da América S.A (DASA3) currently trades at R$2.65, while our model-based Fair Value estimate is R$1.15, implying the stock looks roughly 130.4% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of R$11.32 per share, and 4 of the 8 models we run sit above the R$2.65 price.
Bear case: the Earnings-Based group reads lowest at R$1.81, and 4 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: R$0.7200 (bear) to R$1.50 (bull), the price of R$2.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Diagnósticos da América S.A reported revenue of R$11.2B in FY2025 versus R$10.4B in FY2021, a compound +1.8%/yr. Reported net income was −R$1.2B in FY2025.
Key figures
Market cap R$3.3B (≈ $649M) · P/S ratio 0.35 · EPS (TTM) R$−0.8200 · Dividend yield 0.1% · Net margin −10.3% · Return on equity −13.8% · Return on assets (EBIT) 3.4% · Operating margin 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 125% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −57%, DASA3 screens richer than that median.
Fair Value models
Bear R$0.7200Fair Value R$1.15Bull R$1.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.9% (2020) → 9.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Diagnósticos da América S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score37 · Bottom 25%
Profitability
Return on assets3% · Above median
Net margin (TTM)−11% · Bottom 25%
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth−42% · Bottom 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.84× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.09× · Cheapest 25%
P/S (TTM)0.07× · Cheapest 25%
EV/EBITDA2.6× · Cheapest 25%
PEG0.64× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 27
PAST (return on equity)0· sector 9
HEALTH (low debt)58· sector 96
DIVIDEND (yield)3· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Diagnósticos da América S.A Fair Value". https://www.fairvalue-calculator.com/stock/DASA3
Frequently asked questions
Is Diagnósticos da América S.A (DASA3) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of R$1.15 versus a price of R$2.65, about −57% upside (overvalued).
What is the fair value of DASA3?
Our model-based fair value for Diagnósticos da América S.A is R$1.15 (as of Sep 13, 2026), built from audited fundamentals. The current price: R$2.65.
What is the quality score of DASA3?
Diagnósticos da América S.A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diagnósticos da América S.A (DASA3)?
Our model-based price target is the fair value of R$1.15 (as of Sep 13, 2026) from 8 valuation models. Cautious scenario R$0.7200, optimistic scenario R$1.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Diagnósticos da América S.A stock forecast for 2026?
Our models put fair value at R$1.15, about −57% upside versus a price of R$2.65 (overvalued). Cautious scenario R$0.7200, optimistic scenario R$1.50. The calculation is refreshed regularly with new filings.
What is the revenue of Diagnósticos da América S.A (DASA3)?
Diagnósticos da América S.A reported trailing-twelve-month revenue of about R$9.6B (latest available figure, as of Sep 13, 2026).
Does Diagnósticos da América S.A pay a dividend?
Diagnósticos da América S.A currently shows a dividend yield of about 0.14% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Diagnósticos da América S.A (DASA3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diagnósticos da América S.A it is R$1.15 per share (as of Sep 13, 2026), against a price of R$2.65. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Diagnósticos da América S.A stock overvalued or undervalued in 2026?
As of Sep 13, 2026, DASA3 trades above its calculated fair value: price R$2.65, fair value R$1.15, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DASA3?
No. The price is what the market pays today (R$2.65); the fair value is what the company's own numbers justify (R$1.15). For Diagnósticos da América S.A the two are R$1.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Diagnósticos da América S.A worth?
The market values Diagnósticos da América S.A at about R$3.3B (market capitalisation, as of Sep 13, 2026). Per share that is R$2.65; our models calculate a fair value of R$1.15 per share.
What do the bullish and bearish scenarios say about DASA3?
Our models span a range for Diagnósticos da América S.A: cautious scenario R$0.7200, base R$1.15, optimistic R$1.50 per share (as of Sep 13, 2026, price R$2.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of DASA3?
The PEG ratio of Diagnósticos da América S.A is 0.64 (P/E divided by earnings growth, as of Sep 13, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Diagnósticos da América S.A (DASA3)?
Balance-sheet figures for Diagnósticos da América S.A (as of Sep 13, 2026): return on equity −13.8%, debt of 0.84 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is DASA3 from its 52-week high?
Diagnósticos da América S.A trades at R$2.65, about 44% below its 52-week high of R$4.77 and 125% above the low of R$1.18 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of R$1.15 is for.
Which stocks are comparable to Diagnósticos da América S.A?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diagnósticos da América S.A stock attractive at the current price?
The data as of Sep 13, 2026: price R$2.65, calculated fair value R$1.15 (−57%), Quality Score 37/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DASA3 calculated?
We run Diagnósticos da América S.A through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$1.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Diagnósticos da América S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Diagnósticos da América S.A right now?
The price sits above even our optimistic bull case (R$1.50). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (R$0.7200 to R$1.50) leaves room in how you read the outcome.
Key figures of Diagnósticos da América S.A
How large is the market capitalisation of Diagnósticos da América S.A (DASA3)?
The market capitalisation of Diagnósticos da América S.A is R$3.3B (≈ $649M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diagnósticos da América S.A (DASA3)?
The price-to-sales ratio of Diagnósticos da América S.A is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Diagnósticos da América S.A (DASA3)?
Earnings per share at Diagnósticos da América S.A are R$−0.8200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Diagnósticos da América S.A (DASA3)?
The dividend yield of Diagnósticos da América S.A is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Diagnósticos da América S.A (DASA3)?
The net margin of Diagnósticos da América S.A is −10.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diagnósticos da América S.A (DASA3)?
The return on equity (ROE) of Diagnósticos da América S.A is −13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diagnósticos da América S.A (DASA3)?
On an EBIT basis the return on assets of Diagnósticos da América S.A is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diagnósticos da América S.A (DASA3)?
The operating margin of Diagnósticos da América S.A is 13.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diagnósticos da América S.A (DASA3)?
Revenue at Diagnósticos da América S.A is growing −41.9% versus a year earlier (3y avg −5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diagnósticos da América S.A (DASA3)?
Earnings per share at Diagnósticos da América S.A are growing +30.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Diagnósticos da América S.A (DASA3) generate?
The free cash flow of Diagnósticos da América S.A is −R$307M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Diagnósticos da América S.A (DASA3) carry?
The net debt of Diagnósticos da América S.A is R$6.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Diagnósticos da América S.A in the live analysis
One click puts Diagnósticos da América S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
